Zika virus (ZIKV), a mosquito-borne virus belonging to the genus *Flavivirus* of the family *Flaviviridae*, is transmitted to humans by *Aedes* mosquito species^[@R1],[@R2]^. Several neurological complications, such as Guillain-Barré syndrome in adults^[@R3]^ and microcephaly in neonates^[@R4]^, are potentially associated with ZIKV infection. Before 2007, cases of ZIKV infection were only sporadically detected^[@R2],[@R5]^. The first reported mild ZIKV outbreak occurred in 2007 on a Western Pacific Micronesian Yap Island^[@R6]^. In 2013, a larger ZIKV epidemic was recorded in French Polynesia and other Southern Pacific islands^[@R7],[@R8]^. In 2015, ZIKV emerged in the Americas for the first time, rapidly spreading to 20 countries or territories^[@R9]^. Phylogenetic studies have revealed that ZIKV has evolved into African and Asian clusters^[@R2],[@R9]^. Sequence analyses revealed that the ZIKV strains causing earlier outbreaks in Micronesia (2007) and French Polynesia (2013-2014) and later outbreaks in the Americas (2015-2016) all belong to the Asian clade^[@R2]^, suggesting that increased infectivity of the Asian ZIKV lineage might contribute to the recent worldwide epidemic.

Evolutionary enhancement of infectivity of mosquito-borne viruses within their vectors results in high epidemic potential^[@R10],[@R11]^. We speculate that the adaptability and infectivity of ZIKV within its mosquito vectors might have evolved with time, contributing to the prevalence and spread of the virus from Asia to the Americas. To test this hypothesis, we compared the viral infectivity of two clinical ZIKV isolates of the Asian lineage, GZ01 isolated in 2016^[@R12]^ and FSS13025 in 2010^[@R13]^, in the primary urban mosquito vector, *Aedes aegypti*. Phylogenetic analysis shows that these 2 strains represent the clades corresponding to the epidemic strains of ZIKV that are prevalent in Americas (2015-2016) and the Southeastern Asia (2007-2012) ([Extended Data Fig. 1](#F1){ref-type="fig"}). Thus, we exploited a \"host-mosquito\" acquisition model to assess the infectivity of these ZIKV strains, via mosquitoes acquiring ZIKV from a viremic AG6 mouse ^[@R14]--[@R16]^ ([Fig. 1a](#F10){ref-type="fig"}). Both strains exhibited similar replication kinetics in the infected AG6 mouse blood ([Fig. 1b](#F10){ref-type="fig"}). However, the serum level of secreted nonstructural protein 1 (NS1) in the FSS13025-infected AG6 mice was much lower ([Fig. 1c](#F10){ref-type="fig"}). The infected mice were subjected to daily biting by the Rockefeller laboratory strain of *A. aegypti* from days 1 to 5 post-mouse infection ([Fig. 1a](#F10){ref-type="fig"}). Compared to the GZ01 strain, the FSS13025 strain had a significantly lower infection prevalence in the mosquitoes that fed on the infected mice ([Fig. 1d, e](#F10){ref-type="fig"}).

Secretion of NS1, a virus-encoded nonstructural protein, into the serum of an infected host is a common property of many flaviviruses^[@R15],[@R17]--[@R20]^. Our previous study demonstrated that circulating NS1 acquired by mosquitoes together with virions when mosquitoes feed on a viremic mammalian host enhances viral infectivity^[@R15]^. NS1 antigenemia plays a key role in maintaining the flavivirus life cycle^[@R15]^. We hypothesize that NS1 antigenemia is responsible for the differential mosquito infectivity between the GZ01 and FSS13025 strains. We therefore infected Vero cells with the American isolates GZ01 and PRVABC59^[@R21]^, the SZ01 strain representing the French Polynesian clade^[@R22]^, and the FSS13025 strain. Three post-epidemic strains showed higher NS1 secretion than the FSS13025 strain ([Fig. 2a--c](#F11){ref-type="fig"}), even when NS1 amount was normalized to viral titer ([Fig. 2c](#F11){ref-type="fig"}).

To determine whether NS1 secretability correlates with ZIKV infectivity in mosquitoes, we generated a murine NS1 polyclonal antibody ([Extended Data Fig. 2a](#F2){ref-type="fig"}). Neutralization of NS1 via the antibody treatment reduced the mosquito infection prevalence of the GZ01 strain ([Fig. 2d--f](#F11){ref-type="fig"}). The murine NS1 antibodies did not neutralize ZIKV virions ([Extended Data Fig. 3](#F3){ref-type="fig"}). We also determined whether the addition of NS1 protein could enhance ZIKV infectivity. A recombinant GZ01 NS1 protein was expressed and purified using a *Drosophila* S2 expression system ([Extended Data Fig. 2b](#F2){ref-type="fig"}). The presence of NS1 increased the infectivity of the FSS13025 strain in mosquitoes ([Fig. 2g--i](#F11){ref-type="fig"}). We next assessed the threshold concentration of NS1 that can effectively enhance ZIKV acquisition. Compared to BSA, the presence of 100 ng/ml or higher concentrations of NS1 significantly increased the ZIKV prevalence in *A. aegypti* ([Fig. 2j--l](#F11){ref-type="fig"}). To determine the role of animal NS1 antigenemia in ZIKV infectivity in mosquitoes, we allowed mosquitoes to feed on viremic AG6 mice ([Extended Data Fig. 4a](#F4){ref-type="fig"}). The NS1 antisera treatment reduced the quantity of circulating NS1 in mouse serum ([Extended Data Fig. 4b](#F4){ref-type="fig"}) but did not influence GZ01 ZIKV replication in AG6 mice ([Extended Data Fig. 4c](#F4){ref-type="fig"}). The infection ratios of fed *A. aegypti* were reduced as a result of the antisera-mediated neutralization of the NS1 in mice ([Extended Data Fig. 4d, e](#F4){ref-type="fig"}).

Considering the differential secretability of NS1 between the GZ01 and FSS13025 strains ([Fig. 1c](#F10){ref-type="fig"} and [Fig. 2a--c](#F11){ref-type="fig"}), we next attempted to identify the amino acids critical for NS1 secretion. We focused on the ER transmembrane region of pre-Membrane (prM), the full length of Envelope (E), and NS1 (prM-E-NS1)^[@R23]^ ([Fig. 3a](#F12){ref-type="fig"}). There are only two variable sites between the GZ01 and FSS13025 prM-E-NS1 proteins, including the 473^rd^ residue in the E protein (Val/FSS13025 to Met/GZ01) and the 188^th^ residue in the NS1 protein (Ala/FSS13025 to Val/GZ01) ([Fig. 3a](#F12){ref-type="fig"}). We therefore individually subcloned the *prM*-*E*-*NS1* region from the GZ01 and FSS13025 strains and subsequently transfected these segments into 293T cells. Ectopic expression of the GZ01 prM-E-NS1 protein, but not the FSS13025 protein, led to abundant NS1 secretion in the supernatants of transfected cells ([Fig. 3b](#F12){ref-type="fig"}). Mutation from valine to methionine at the 473^rd^ residue of the E protein in the FSS13025 prM-E-NS1 protein did not improve NS1 secretion; however, the alanine to valine substitution at the NS1 188^th^ residue rendered NS1 secretable ([Fig. 3b](#F12){ref-type="fig"}), demonstrating that this single mutation determines NS1 secretability. The 188th residue is located within interface between two NS1 monomers^[@R24]^ ([Extended Data Fig. 5a](#F5){ref-type="fig"}). Nonetheless, the alanine-to-valine substitution at position 188 does not influence NS1 dimerization ([Extended Data Fig. 5b](#F5){ref-type="fig"}), suggesting that the mechanism how the single mutation affects NS1 remains to be defined.

We next performed an alignment of the NS1 proteins from the Asian clade of ZIKV. In ZIKV isolates collected before 2012, the 188^th^ residue of the NS1 protein is an alanine. However, this residue is mutated to valine in all isolates after 2013 ([Extended Data Fig. 6](#F6){ref-type="fig"}), suggesting that the Asian linage of ZIKV evolved to acquire NS1 secretability when it spread from Southeastern Asia to the Southern Pacific islands around 2013. Correspondingly, Singapore reported local ZIKV transmission in August 2016. The Singaporean strains stemmed from an ancestral node of the Asian lineage^[@R25]^. Indeed, in all ZIKV isolates from Singapore, the 188^th^ residue of the NS1 protein is a valine ([Extended Data Fig. 6](#F6){ref-type="fig"}), suggesting that the alanine-to-valine substitution may have contributed to the recent ZIKV epidemics. Therefore, we synthesized the *prM-E-NS1* genes from a Malaysia P6-740 strain isolated in 1966 and a Micronesian 2007 strain and ectopically expressed these genes in 293T cells. Compared to the secretion of NS1 in the supernatants of GZ01 *prM-E-NS1*-transfected cells, the NS1 protein was hardly detectable in the supernatants of these pre-epidemic ZIKV *prM-E-NS1*-expressing cells ([Fig. 3c](#F12){ref-type="fig"}). However, the alanine-to-valine mutation in the NS1 protein of the P6-740 strain conferred NS1 secretability ([Fig. 3d](#F12){ref-type="fig"}).

Next, we created the alanine-to-valine mutation at the 188^th^ position of the NS1 protein in an infectious clone of the FSS13025 strain (FSS13025-A188V)^[@R26]^. The substitution significantly increased NS1 secretion in the supernatant of infected Vero cells ([Extended Data Fig. 7a--c](#F7){ref-type="fig"}). The FSS13025-A188V strain showed higher ZIKV infectivity in mosquitoes than wild type virus ([Extended Data Fig. 7d, e](#F7){ref-type="fig"}). In the \"mouse-mosquito\" acquisition model, NS1 antigenemia was increased in the sera of FSS13025-A188V ZIKV-infected mice ([Fig. 3e](#F12){ref-type="fig"}). Mutation of the NS1 188^th^ position did not influence viral infectivity or dissemination kinetics in infected AG6 mouse blood ([Fig. 3f](#F12){ref-type="fig"}). However, the substitution enhanced ZIKV transmission from mice to mosquitoes ([Fig. 3g, h](#F12){ref-type="fig"}). Moreover, neutralization of NS1 with murine ZIKV NS1 antisera effectively reduced the prevalence of FSS13025-A188V ZIKV in mosquitoes ([Extended Fig. 8a--d](#F8){ref-type="fig"}), highlighting that the 188^th^ valine in NS1 has a critical role in the antigenemia, which is critical for ZIKV acquisition by mosquitoes.

We next investigated whether NS1-mediated enhancement of ZIKV infectivity influences the prevalence of ZIKV-carrying mosquitoes using a \"mosquito-mouse-mosquito\" transmission cycle. We thoracically inoculated an equal titer (5 pfu) of the GZ01, FSS13025 and FSS13025-A188V mutant strains, into female *A. aegypti* mosquitoes. Six days following virus inoculation, two infected mosquitoes were allowed to feed on AG6 mice ([Fig. 4a](#F13){ref-type="fig"}). The mosquito-bitten animals developed high-titer viremia of all three ZIKV strains ([Fig. 4b](#F13){ref-type="fig"}). Replication of both the GZ01 and FSS13025-A188V ZIKV strains, but not the FSS13025 strain, resulted in efficient NS1 antigenemia ([Fig. 4c](#F13){ref-type="fig"}). Subsequently, the infected mice were subjected to daily biting by naïve *A. aegypti* from days 1 to 8 post-mouse infection ([Fig. 4a](#F13){ref-type="fig"}). Through a complete transmission cycle, the FSS13025-A188V strain showed a significantly higher prevalence of mosquito infection than did the FSS13025 strain ([Fig. 4d, e](#F13){ref-type="fig"}), demonstrating that the 188^th^ valine is required for the generation of NS1 antigenemia which enhances ZIKV transmissibility from hosts to vectors.

ZIKV independently separated into African and Asian lineages. We found that the 188^th^ residue in all ZIKV African strains is valine ([Extended Data Fig. 9a](#F9){ref-type="fig"}). The Uganda MR766-infected Vero cells abundantly secreted NS1 ([Extended Data Fig. 9b--d](#F9){ref-type="fig"}), implicating that infection of the African ZIKV might produce high NS1 antigenemia. ZIKV has two ecologically distinct transmission cycles: a sylvatic cycle (mosquitoes to non-human primates) and a human cycle (mosquitoes to humans)^[@R27]^. Knowledge of ZIKV before 2012 was almost exclusively centered on the enzootic sylvatic cycle in Africa^[@R27],[@R28]^. A mosquito survey in Africa showed that ZIKV was detected in mosquitoes collected in multiple surveyed landscapes, except for indoor locations within villages^[@R28]^. Therefore, we hypothesize that the presence of the NS1 188^th^ valine might bestow the African lineage of ZIKV with a highly efficient enzootic or epizootic transmission cycle^[@R27],[@R28]^. Other unknown factor(s) might prevent African ZIKV from efficiently establishing a human cycle. However, the Asian strains may have evolved to target humans with high infectivity; indeed, one such strains caused a medium-scale epidemic in Micronesia in 2007^[@R2],[@R6]^. The alanine-to-valine substitution at position 188 further improved ZIKV transmission efficiency from humans to mosquitoes and thus increased its prevalence in mosquitoes. Our data offer a potential explanation for the recent re-emergence of ZIKV, and suggest that coevolution of arboviruses with their hosts/vectors contributes to their long-term existence in nature and occasional widespread re-emergence.

Methods {#S2}
=======

Ethics statement {#S3}
----------------

Human blood for mosquito feeding was taken from healthy donors who provided written informed consent. The collection of human blood samples was approved by the local ethics committee at Tsinghua University.

Mice, mosquitoes, cells and viruses {#S4}
-----------------------------------

AG6 mice were donated from Institute Pasteur of Shanghai, Chinese Academy of Sciences^[@R5]^. The mice were bred and maintained under a specific pathogen-free animal facility at Tsinghua University. Groups of age- and sex-matched AG6 mice, 6--8 weeks of age, were used for the animal studies^[@R15]^. All experiments were approved by and performed under the guidelines of the Experimental Animal Welfare and Ethics Committee of Tsinghua University. *A. aegypti* (Rockefeller strain) were reared in a low-temperature, illuminated incubator (Model 818, Thermo Electron Corporation, Waltham, MA) at 28 °C and 80% humidity according to standard rearing procedures^[@R29]^. The ZIKV GZ01 strain (*KU820898*), PRVABC59 (*KU501215*), SZ01 strain (*KU866423*), MR766 (*NC_012532*) and FSS13025 strain (*KU955593*) were grown in Vero cells for blood meals^[@R15]^. The *Drosophila melanogaster* S2 cell line was cultured in Schneider's medium with 10% heat-inactivated fetal bovine serum and 1% antibiotic--antimycotic (15240-062, Invitrogen). The Vero cells and 293T cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM, Gibco) supplemented with 10% heat-inactivated fetal bovine serum (16000-044, Gibco). For ZIKV infection, the Vero cells were maintained in VP-SFM medium (11681-020, Gibco). The Vero and 293T cell lines were purchased from the ATCC (CCL-81, CRL-3216). The *Drosophila* S2 cell line was sourced from a *Drosophila* expression system of Invitrogen (R690-07). None of these cell lines were found in the database of commonly misidentified cell lines maintained by ICLAC and NCBI Biosample. All these cell lines were authenticated by ATCC or Invitrogen and do not have mycoplasma contamination. ZIKV was titered by a plaque formation (PFU) assay^[@R29]^.

Antibodies {#S5}
----------

The ZIKV *NS1* genes were amplified from the cDNA of infected cells and cloned into a pET-28a (+) expression vector (69864, Millipore). The cloning primers are presented in [Extended Data Table 1](#T1){ref-type="table"}. Recombinant NS1 proteins were expressed in the *Escherichia coli* BL21 DE3 strain in an insoluble form in inclusion bodies. The proteins were then solubilized by 8 M urea and purified with a TALON Purification Kit (635515, Clontech). Murine antisera were produced via the inoculation of recombinant ZIKV NS1 with 3 boosts. Polyclonal antibodies were purified from the immunized antisera using Protein A/G agarose (20423, Thermo). The anti-V5-HRP antibody for tag detection were purchased from Invitrogen (R96125, Thermo).

Expression of prM-E-NS1 protein in human cells {#S6}
----------------------------------------------

The *prM-E-NS1* regions (820 bp-3438 bp in GZ01 *KU820898*; 927 bp-3544 bp in FSS13025 *KU955593*) were amplified from cDNA of infected cells. The *prM-E-NS1* genes from the P6-740 strain (820 bp-3438 bp, *HQ234499*) and the Micronesian 2007 strain (820 bp-3438 bp, *EU545988*) were commercially synthesized (Genescript, China). All the genes were subcloned into a pcDNA3.1/V5-His/TOPO DNA vector (K4800-01, Invitrogen), and subsequently transfected by the X-treme Gene HP DNA transfection reagent (06366236001, Roche) for ectopically expression in 293T cells. The amount of NS1 was determined in the supernatants of the 293T cells at 48 hrs post-transfection. The cloning primers are shown in [Extended Data Table 1](#T1){ref-type="table"}.

ZIKV NS1 protein generation in a *Drosophila* expression system {#S7}
---------------------------------------------------------------

The ZIKV *NS1* gene was cloned into a pMT/BiP/V5-His A vector (V4130-20, Invitrogen) for expression in *Drosophila* S2 cells. The cloning primers are shown in [Extended Data Table 1](#T1){ref-type="table"}. The procedure for ZIKV NS1 expression and purification in a *Drosophila* expression system has been described in our previous studies^[@R15],[@R29]^.

ZIKV NS1 detection by ELISA {#S8}
---------------------------

Secretion of ZIKV NS1 into Vero cell supernatant and mouse serum was measured using a ZIKV NS1 Antigen ELISA Kit (ZIKV-NS1-EK, BioFront MonoTrace). The experiment was performed according to the kit's manual. Samples were diluted to the range of quantification of the kit using the sample dilution buffer provided in the kit. Standard materials for the generation of a standard curve were also provided in the kit. The measured amount of ZIKV NS1 matched the linearity in the assay. Optical density (OD) was measured at 450 nm with an ELISA reader (Varioskan Flash Multimode Reader, Thermo Scientific). The detection limit of NS1 protein by ELISA is 0.1 ng/ml.

Thoracic inoculation of ZIKV in mosquitoes {#S9}
------------------------------------------

Detailed procedures for microinjection in mosquitoes have been described by our previous studies^[@R15],[@R30]^. Briefly, the female *A. aegypti* mosquitoes were anesthetized on a cold tray, and subsequently a certain titer of ZIKV was microinjected into the mosquito thoraxes. The infected mosquitoes were used for ZIKV transmission to AG6 mice by a blood meal.

Membrane blood feeding {#S10}
----------------------

Fresh human blood was placed in heparin-coated tubes (367884, BD Vacutainer) and centrifuged at 1,000×g and 4 °C for 10 min to separate the plasma from the blood cells. The plasma was collected and heat-inactivated at 55 °C for 60 min. The separated blood cells were washed 3 times with PBS to remove the anticoagulant. The cells were then resuspended in the heat-inactivated plasma. The donor\'s sera were negative for detection of the E and NS1 proteins of JEV, DENV and ZIKV. Either purified proteins or antibodies were mixed with the ZIKV-infected supernatant and human blood for mosquito oral feeding via a Hemotek system (6W1, Hemotek Limited, England). Engorged female mosquitoes were transferred into new containers and maintained under standard conditions for an additional 8 days. The mosquitoes were subsequently sacrificed for further analysis.

Mosquito feeding on infected mice {#S11}
---------------------------------

Eight to ten female *A. aegypti* mosquitoes were separated into a netting-covered container for blood feeding. The mosquitoes were starved for 24 hr before engorgement. ZIKV-infected AG6 mice were anesthetized and placed on top of the container. The mosquitoes were allowed to feed on the mice for 30 min in the dark. After anesthetization using ice, the engorged mosquitoes were transferred to new containers and maintained under standard conditions for an additional 8 days. The mosquitoes were subsequently sacrificed for further analysis.

Purification of infectious ZIKV virions {#S12}
---------------------------------------

The procedure of purification of flaviviral infectious virions has been described in our previous study^[@R15]^. Briefly, supernatant from GZ01-infected Vero cells was collected 5 days after infection. Cell fragments were removed by centrifugation at 25,000×g and 4 °C for 20 min. Subsequently, the supernatant was carefully transferred into a clean centrifuge tube and centrifuged at 25,000×g and 4 °C for an additional 6 h to pellet the virions. The precipitated virions were washed twice and then solubilized in VP-SFM medium (11681-020, Gibco). Insoluble material was removed by an extra centrifugation step at 12,000×g and 4 °C for 2 min. The virions in the VP-SFM medium were aliquoted and stored at -80 °C.

Viral genome quantitation by TaqMan qPCR {#S13}
----------------------------------------

Total RNA was isolated from homogenized mosquitoes using an RNeasy Mini Kit (74106, Qiagen) and reverse-transcribed into cDNA using an iScript cDNA synthesis kit (170-8890, Bio-Rad). Viral genomes were quantified via TaqMan qPCR amplification of ZIKV genes, normalized against *A. aegypti actin* (*AAEL011197*). The detection limit of ZIKV E/Actin mRNA ratio is 0.001. The primers and probes used for this analysis are shown in [Extended Data Table 1](#T1){ref-type="table"}.

Determination of the virus titer in infected mice by plaque assay {#S14}
-----------------------------------------------------------------

Blood samples were collected from the tail veins of infected mice in 0.4% sodium citrate and were centrifuged for 5 min at 6,000×g and 4 °C for plasma isolation. The presence of infectious viral particles in the plasma was determined using a plaque assay^[@R15]^. The detection limit in the plaque assay is 10 pfu/ml in cell supernatant, and 100 pfu/ml in serum.

RNA transcription, transfection and virus recovery {#S15}
--------------------------------------------------

The pFLZIKV-FSS13025 and pFLZIKV-FSS13025-A188V^[@R26]^ plasmids were amplified in *E. coli* Top10 (C404010, Invitrogen) and purified using MaxiPrep PLUS (12965, QIAGEN). For *in vitro* transcription, 10 μg of plasmid was linearized with the restriction enzyme ClaI. A mMESSAGE mMACHINE T7 kit (AM1344, Ambion) was used for *in vitro* transcription of RNA in a 20 μl reaction with an additional 1 μl of 30 mM GTP solution. The RNA was precipitated with lithium chloride and quantified via spectrophotometry. Subsequently, the RNA was transfected into Vero cells seeded in a T175 flask with DMEM medium and incubated at 37°C and 5% CO~2~ using Lipofectamine 3000 reagent (L3000015, Invitrogen). Recombinant viruses in cell culture media were harvested 4 days post transfection, stored in aliquots at -80°C, and subjected to further investigation.

Statistics {#S16}
----------

Animals were randomly allocated into different groups. Mosquitoes that died before measurement were excluded from analysis. The investigators were not blinded to the allocation during the experiments or to the outcome assessment. No statistical methods were used to predetermine the sample size. Descriptive statistics have been provided in the figure legends. Kruskal-Wallis analysis of variance was conducted to detect any significant variation among replicates. If no significant variation was detected, the results were pooled for further comparison. Given the nature of the experiments and the type of samples, differences in continuous variables were assessed with a non-parametric Mann-Whitney test. Differences in mosquito infective rates were analyzed using Fisher's exact test. *p* values were adjusted using Bonferroni correction to account for multiple comparisons. All analyses were performed using GraphPad Prism statistical software.

Data availability {#S17}
-----------------

Source data for the main and Extended Data Figures are provided in the online version of this paper. All other data are available from the corresponding authors upon reasonable request.

Extended Data {#S1}
=============

![Phylogenetic analysis of ZIKV isolates in the Asian lineage\
The tree was constructed using the neighbor-joining (NJ) method based on the alignment of ZIKV sequences in the Asian lineage. The bootstrap values of 2000 replicates are indicated on the branch nodes.](nihms867392f1){#F1}

![Generation of murine anti-ZIKV NS1 polyclonal antibody and purification of the GZ01 ZIKV NS1 protein from *Drosophila* S2 cells\
**a**, Generation of murine anti-ZIKV NS1 polyclonal antibody. A murine ZIKV NS1 polyclonal antibody was generated by immunization of the purified GZ01 ZIKV NS1 recombinant protein expressed in E. coli. The antibody was validated by probing an S2-expressed ZIKV NS1 recombinant protein. The same samples probed by murine pre-immune antibody served as a negative control.\
**b**, Purification of the GZ01 ZIKV NS1 protein from *Drosophila* S2 cells. Full-length *NS1* was cloned into the pMT/BiP/V5-His A expression vector. Recombinant ZIKV NS1 protein was expressed in *Drosophila* S2 cells and purified using a cobalt-His column (Left Panel). Protein quality was evaluated by Western-blotting with an anti-V5 antibody (Right Panel).\
**a**, **b**, The experiments were reproduced 3 times with similar results. For gel source data, see [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}.](nihms867392f2){#F2}

![Anti-ZIKV NS1 antibodies did not neutralize ZIKV virions\
We premixed two dilutions of murine ZIKV NS1 polyclonal antisera (1:100 and 1:1000) with purified ZIKV GZ01 infectious virions. The same amount of pre-immune sera served as a negative control. After a 30 min incubation, the infectivity of the \"antibody-ZIKV virion\" mixture was determined by plaque assay on Vero cells. The values in the graph represent the mean ± s.e.m. *p* values were determined by two-tailed Mann-Whitney test. The data were combined from 3 biological repeats. n.s., not significant.](nihms867392f3){#F3}

![Passive transfer of ZIKV NS1 antibodies into infected AG6 mice prevented ZIKV acquisition by *A. aegypti*\
**a**, Schematic representation of the study design. AG6 mice were intradermally infected with 1×10^4^ pfu of the ZIKV GZ01 strain. Subsequently, 100 μl of a murine ZIKV NS1 antibody was intraperitoneally inoculated into the mice 12 hr post-infection. The same amount of pre-immune serum was inoculated as a mock control. After 12 hr of antibody dissemination, the infected mice were subjected to daily biting by female *A. aegypti* from day 1 to day 5 post-mouse infection. The mouse blood-fed mosquitoes were reared for an additional 8 days for ZIKV detection.\
**b**, ZIKV NS1 measurement by ELISA (n=6 mice per group pooled from 3 independent biological replicates). Mouse sera were collected to quantify the amounts of ZIKV NS1 protein from days 0 and 6 post-mouse infection.\
**c**, Detection of the ZIKV load in the blood of the infected mice (n=8 mice per group pooled from 4 independent biological replicates). The presence of infectious ZIKV particles in blood plasma was determined by a plaque assay from days 0 to 6 post-mouse infection.\
**d**, **e**, Immuno-blockade of ZIKV NS1 in infected AG6 mice reduced the infection of fed *A. aegypti* (n=6 mice per group pooled from 3 independent biological replicates). The number of infected mosquitoes relative to the total number of mosquitoes is shown at the top of each column. Each dot represents a mosquito (**d**). The data are represented as the percentage of mosquito infection (**e**).\
Data are mean ± s.e.m. (**b**, **c**). *p* values were determined by two-tailed Mann-Whitney test (**b**-**d**) or two-sided Fisher's exact test (**e**). \*\**p*\< 0.01, \*\*\**p*\< 0.001, n.s., not significant.](nihms867392f4){#F4}

![Modeling the location of the 188^th^ residue of ZIKV NS1 and assessing NS1 dimer formation in cell lysates\
**a**, Modeling the location of the 188^th^ residue of ZIKV NS1. Modeling was based on the ZIKV NS1 structure (PDB: 5K6K)^[@R30]^. The 188^th^ position is located within the interface of a NS1 dimer (contoured by red), which is formed by hydrophobic interactions. The 188^th^ amino acid is deep within the hydrophobic pocket formed by Trp-210, Leu-23, His-299 and Leu-231.\
**b**, Assessing NS1 dimer formation in the lysates of cells transfected with GZ01 or FSS13025 *prM-E-NS1* recombinant plasmids. The cell lysates, with or without heating treatment, were used for assessing NS1 monomer and dimer by Western blotting with an anti-V5 antibody, respectively. The experiment was reproduced 3 times with similar results. For gel source data, see [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}.](nihms867392f5){#F5}

![Sequence alignment of NS1 sequences in ZIKV isolates of the Asian lineage.](nihms867392f6){#F6}

![A single amino acid substitution enhanced NS1 secretability and ZIKV infectivity in mosquitoes\
**a--c**, NS1 secretability in ZIKV-infected Vero cells. We mutated the single amino acid from alanine to valine at the 188^th^ position of NS1 protein on an infectious clone of ZIKV Cambodian FSS13025 strain (FSS13025-A188V strain). FSS13025 or FSS13025-A188V strain (0.01 M.O.I.) was used to infect Vero cells. Supernatants from the infected Vero cells were collected from 0 to 5 days post-infection. **a**, The amount of ZIKV NS1 protein was determined by ELISA. **b**, ZIKV titer was determined by a plaque assay. **c**, NS1 quantity normalized against average viral titer (ng per pfu). The data were pooled from 3 independent biological replicates.\
**d--e**, NS1 secretability determined ZIKV infectivity in mosquitoes. The supernatant, isolated from the FSS13025-infected or FSS13025-A188V-infected Vero cells, was premixed with fresh human blood at a 1:1 ratio for an *in vitro* membrane feeding experiment (final titer is 5×10^4^ pfu/ml), respectively. The fed mosquitoes were scarified on 8 days after a blood meal to determine the ZIKV load by qPCR. The number of infected mosquitoes relative to the total number of mosquitoes (infected number/total number) is shown at the top of each column. Each dot represents a mosquito (**d**). The data are represented as the percentage of mosquito infections (**e**). The data were pooled from 3 independent biological replicates.\
Data are mean ± s.e.m. (**a**-**c**). *p* values were determined by two-tailed Mann-Whitney test (**a**-**d**) or two-sided Fisher's exact test (**e**). \**p*\< 0.05, \*\**p*\< 0.01, n.s., not significant.](nihms867392f7){#F7}

![Neutralization of NS1 by murine ZIKV NS1 antisera effectively reduced the prevalence of FSS13025-A188V ZIKV in *A. aegypti*\
**a, b**, Infection by FSS13025-A188V ZIKV in AG6 mice. The AG6 mice were intradermally inoculated with these viruses (1×10^4^ pfu). ZIKV NS1 measurement by ELISA. Mouse sera were collected to qualify the amounts of ZIKV NS1 protein from days 0 to 6 post-mouse infection (**a**). Detection of the ZIKV load in the blood of infected AG6 mice. The presence of infectious ZIKV particles in blood plasma was determined by a plaque assay (**b**). n=10 mice per group pooled from 4 independent biological replicates.\
**c, d**, Immuno-blockade of NS1 in the FSS13025-A188V ZIKV infected AG6 mice reduced the acquisition of fed *A. aegypti* (n=7 mice per group pooled from 3 independent biological replicates). The number of infected mosquitoes relative to the total number of mosquitoes is shown at the top of each column. Each dot represents a mosquito (**c**). The data are represented as the percentage of mosquito infection (**d**).\
Data are mean ± s.e.m. (**a**, **b**). *p* values were determined by two-tailed Mann-Whitney test (**a**-**c**) or two-sided Fisher's exact test (**d**). \**p*\< 0.05, \*\*\**p*\< 0.001, n.s., not significant.](nihms867392f8){#F8}

![Sequence alignment of NS1 sequences in African ZIKV isolates, and NS1 secretability in African ZIKV-infected Vero cells\
**a**, Sequence alignment of NS1 sequences in African ZIKV isolates.\
**b-d**, NS1 secretability in African ZIKV-infected Vero cells. Vero cells were infected at an M.O.I. of 0.01 with the GZ01, FSS13025 and MR766 strains. Supernatants from the infected Vero cells were collected from 0 to 4 days post-infection. **b**, ZIKV titer was determined by a plaque assay. **c**, The amount of ZIKV NS1 protein was determined by ELISA. **d**, NS1 quantity normalized against average viral titer (ng per pfu). The data were pooled from 3 independent biological replicates.\
The values in the graph represent the mean ± s.e.m. (**b**-**d**).](nihms867392f9){#F9}
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![Comparing the infectivity of ZIKV isolates of Asian lineage in mosquitoes\
**a**, Schematic representation of the study design. Separated groups of AG6 mice were intradermally infected with 1×10^4^ pfu of the GZ01 and FSS13025 strains.\
**b**, Detection of the ZIKV load in the blood plasma by a plaque assay (n=14 mice per group pooled from 5 independent biological replicates).\
**c**, ZIKV NS1 measurement by ELISA (n=6 mice per group pooled from 3 independent biological replicates).\
**d**, **e**, Comparison of the infectivity of two ZIKV isolates in *A. aegypti* (n=6 mice per group pooled from 3 independent biological replicates). The number at the top of each column represents infected number/total number. Each dot represents a mosquito (**d**). The data are represented as the percentage of mosquito infections (**e**).\
Data are mean ± s.e.m. (**b**, **c**). *p* values were determined by two-tailed Mann-Whitney test (**b**-**d**) or two-sided Fisher's exact test (**e**). \*\**p*\< 0.01, \*\*\**p*\< 0.001, n.s., not significant.](nihms867392f10){#F10}

![Differences in NS1 secretion determine ZIKV infectivity in mosquitoes\
**a**-**c**, NS1 secretability in ZIKV-infected Vero cells. Vero cells were infected with 0.01 M.O.I. viruses. **c**, NS1 quantity normalized against average viral titer (ng per pfu). The data were pooled from 3 independent biological replicates.\
**d-f**, Immunoblockade of NS1 in GZ01-infected supernatants reduced ZIKV acquisition. Either 10 μl of murine ZIKV NS1 antisera or pre-immune sera were mixed with supernatant from ZIKV GZ01-infected Vero cells (500 μl) and fresh human blood (500 μl) for *in vitro* membrane feeding of *A. aegypti*. The data were pooled from 2 independent biological replicates.\
**g-i**, Addition of NS1 in FSS13025-infected supernatant increased the mosquito infection. Either 10 μg of purified NS1 or BSA was incubated with fresh human blood (500 μl) and supernatant from ZIKV FSS13025-infected Vero cells (500 μl) to feed *A. aegypti*. The data were pooled from 2 independent biological replicates.\
**j-l**, Assessment of the threshold NS1 concentration that enhances ZIKV acquisition. Serial dilutions of purified ZIKV NS1 (10 μl) were mixed with purified GZ01 ZIKV virions (10 μl) and fresh human blood (1000 μl) for *A. aegypti* feeding. The data were pooled from 4 independent biological replicates.\
A final concentration of 1×10^5^ pfu/ml ZIKV was used for mosquito oral infection (**d**, **g**, **j**).\
The number at the top of each column represents infected number/total number. Each dot represents a mosquito (**e**, **h**, **k**).\
Data are mean ± s.e.m. (**a**-**c**). *p* values were determined by two-tailed Mann-Whitney test (**e**, **h**, **k**) or two-sided Fisher's exact test (**f**, **i**, **l**), and adjusted using Bonferroni correction to account for multiple comparisons (**k**, **l**). The *p* value represents a comparison between BSA and other groups (**k**, **l**). \**p*\< 0.0125, \*\*\**p*\< 0.00025, n.s., not significant.](nihms867392f11){#F11}

![A single amino acid residue in NS1 determines its secretability in the Asian lineage of ZIKV\
**a**, Comparison of the *prM-E-NS1* sequence between GZ01 and FSS13025 isolates.\
**b**, Detection of NS1 secretion in ectopically expressed prM-E-NS1 proteins of the subcloned and mutated GZ01 and FSS13025 strains.\
**c**, Detection of NS1 secretion in ectopically expressed prM-E-NS1 proteins of ZIKV Asian strains.\
**d**, Mutation of alanine to valine in the NS1 protein conferred NS1 secretability to the prM-E-NS1 proteins of a Malaysia P6-740 strain.\
**b**-**d**, The experiments were reproduced 3 times with similar results. For gel source data, see [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}.\
**e**, Measurement of ZIKV NS1 antigenemia by ELISA (n=10 mice per group pooled from 5 independent biological replicates).\
**f**, Detection of the ZIKV load in the mouse blood by a plaque assay (n=8 mice per group pooled from 4 independent biological replicates).\
**g**, **h**, Comparison of mosquito infectivity (**g**) and infective ratio (**h**) of ZIKV strains (n=6 mice per group pooled from 3 independent biological replicates). The number at the top of each column represents infected number/total number. Each dot represents a mosquito (**g**).\
The AG6 mice were intradermally inoculated with 1×10^4^ pfu of the FSS13025 and FSS13025-A188V strains, data are mean ± s.e.m. (**e**, **f**). *p* values were determined by two-tailed Mann-Whitney test (**e**-**g**) or two-sided Fisher's exact test (**h**). \**p*\< 0.05, \*\*\**p*\< 0.001, n.s., not significant.](nihms867392f12){#F12}

![A single amino acid substitution influences the prevalence of mosquito infection during the \"mosquito-host-mosquito\" life cycle\
**a**, Schematic representation of the study design.\
**b**, Detection of the ZIKV viremia by a plaque assay (n=12 mice per group pooled from 4 independent biological replicates).\
**c**, Measurements of ZIKV NS1 antigenemia by ELISA (n=12 mice per group pooled from 4 independent biological replicates).\
**d**, **e**, Comparison of mosquito infectivity (**d**) and infective ratio (**e**) of ZIKV strains (n=9 mice per group pooled from 3 independent biological replicates). The number at the top of each column represents infected number/total number. Each dot represents a mosquito (**d**).\
Data are mean ± s.e.m. (**b**, **c**). *p* values were determined by two-tailed Mann-Whitney test (**b**-**d**) or two-sided Fisher's exact test (**e**), and adjusted using Bonferroni correction to account for multiple comparisons (**b**-**e**). The black *p* value represents a comparison between GZ01 and FSS13025. The blue *p* value represents a comparison between FSS13025-A188V and FSS13025. \**p*\< 0.025, \*\**p*\< 0.005, \*\*\**p*\< 0.0005, n.s., not significant.](nihms867392f13){#F13}

###### 

Primers and probes for gene cloning and qPCR.

  Primers for cloning into pET28a(+)                  Upper primer                           Lower primer                     
  --------------------------------------------------- -------------------------------------- -------------------------------- -------------------------------------------
  *ZIKV NS1* (His tag m both N and C-terminal)        TATCTAGCTAGCGATGTGGGGTGCTCG            GATTCCGCTCGAGTGCAGTCACCATTGA     
  **Primers for cloning into pMT/BiP/V5-His/A**       **Upper primer**                       **Lower primer**                 
  *ZIKV NS1* (V5 tag in C-terminal)                   TCTCGGGGTACCTGATGTGGGGTGCTCG           TATTACGCTCGAGTGCAGTCACCATTGAC    
  **Primers for cloning into pcDNA3.1/V5-His/TOPO**   **Upper primer**                       **Lower primer**                 
  *Zika prM-E-NS1 (V5 Tag in C-terminal)*             TAAGGCGGTACCGCCACCATGCAAAAAGTCATATAC   TATCCGCTCGAGCGTGCAGTCACCATTGA    
  *FSS13025 V-M mutation (E)*                         ATGTGGTTGGGTCTGAATACAAAGAATGGA         TCCATTCTTTGTATTCAGACCCAACCACAT   
  *FSS13025 A-V mutation (NS1)*                       ATTGGAACAGCCGCTAAGGGAAAGGAGGCT         AGCCTCCTTTCCCTTAGCGGCTGTTCCAAT   
  *P6-740 A-V mutation (NS1)*                         GTCATAGGAACAGCTGTTAAGGGAAAGGAG         CTCCTTTCCCTTAACAGCTGTTCCTATGAC   
  **The primers for Taqman RT-qPCR**                  **Upper primer**                       **Lower primer**                 **Probe (for Taqman QPCR)**
  *ZIKV envelope* gene                                CCGCTGCCCAACACAAG                      CCACTAACGTTCTTTTGCAGACAT         FAM-AGCCTACCTTGACAAGCARTCAGACACTCAA-TAMRA
  *Aedes aegypti actin*                               GAACACCCAGTCCTGCTGACA                  TGCGTCATCTTCTCACGGTTAG           FAM-AGGCCCCGCTCAACCCGAAG-TAMRA
  *Mouse actin*                                       AGCCATGTACGTAGCCATCCA                  TCTCCGGAGTCCATCACAATG            FAM-TGTCCCTGTATGCCTCTGGTCGTACCAC-TAMRA
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